Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
NCT04264598Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (5 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Seroconversion Rates. Started Aug 2017; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT04264598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264598.